

Mohammad Hossein Pourgholami

List of Publications by Year in Descending Order

Source:

<https://exaly.com/author-pdf/2949701/mohammad-hossein-pourgholami-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

77
papers

2,612
citations

33
h-index

48
g-index

77
ext. papers

2,881
ext. citations

5
avg, IF

5.02
L-index

#	Paper	IF	Citations
77	Molecular Pharmacology and Novel Potential Therapeutic Applications of Fingolimod.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 807639	5.6	0
76	Monepantel antitumor activity is mediated through inhibition of major cell cycle and tumor growth signaling pathways. <i>American Journal of Cancer Research</i> , 2021 , 11, 3098-3110	4.4	
75	The role of ERβ6 in cell type-specific functions of estrogen and cancer development. <i>Pharmacological Research</i> , 2021 , 163, 105307	10.2	5
74	The effects of anticancer medicinal herbs on vascular endothelial growth factor based on pharmacological aspects: a review study. <i>Nutrition and Cancer</i> , 2021 , 73, 1-15	2.8	13
73	Expression patterns of ERβ6 and its novel variant isoform ERβ6 in lactotroph pituitary adenomas and associations with clinicopathological characteristics. <i>Pituitary</i> , 2020 , 23, 232-245	4.3	4
72	Long-term Survival and Propensity Score Matched Outcomes of Bilateral Unilateral Diaphragm Interventions in Cytoreductive Surgery plus Intra-peritoneal Chemotherapy. <i>Anticancer Research</i> , 2018 , 38, 5917-5921	2.3	3
71	Neuroprotective effects of astaxanthin in a rat model of spinal cord injury. <i>Behavioural Brain Research</i> , 2017 , 329, 104-110	3.4	31
70	PEGylated Albumin-Based Polyion Complex Micelles for Protein Delivery. <i>Biomacromolecules</i> , 2016 , 17, 808-17	6.9	48
69	MUC1 as a potential target in anticancer therapies. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015 , 38, 108-18	2.7	44
68	Prognostic significance of Ki67 expression in malignant peritoneal mesothelioma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015 , 38, 388-94	2.7	20
67	Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model. <i>Journal of Nanobiotechnology</i> , 2015 , 13, 25	9.4	64
66	Minocycline attenuates hypoxia-inducible factor-1 expression correlated with modulation of p53 and AKT/mTOR/p70S6K/4E-BP1 pathway in ovarian cancer: in vitro and in vivo studies. <i>American Journal of Cancer Research</i> , 2015 , 5, 575-88	4.4	16
65	Human Sprouty1 suppresses growth, migration, and invasion in human breast cancer cells. <i>Tumor Biology</i> , 2014 , 35, 5037-48	2.9	11
64	Involvement of urokinase-type plasminogen activator system in cancer: an overview. <i>Medicinal Research Reviews</i> , 2014 , 34, 918-56	14.4	90
63	Effect of minocycline on pentylenetetrazol-induced chemical kindled seizures in mice. <i>Neurological Sciences</i> , 2014 , 35, 571-6	3.5	22
62	Gene of the month: Interleukin 6 (IL-6). <i>Journal of Clinical Pathology</i> , 2014 , 67, 932-7	3.9	87
61	p70 Ribosomal protein S6 kinase (Rps6kb1): an update. <i>Journal of Clinical Pathology</i> , 2014 , 67, 1019-25	3.9	39

60	Albendazole loaded albumin nanoparticles for ovarian cancer therapy. <i>European Journal of Nanomedicine</i> , 2014 , 6,		9
59	Anticancer properties of novel aminoacetonitrile derivative monepantel (ADD 1566) in pre-clinical models of human ovarian cancer. <i>American Journal of Cancer Research</i> , 2014 , 4, 545-57	4.4	4
58	Oestrogen receptors are prognostic factors in malignant peritoneal mesothelioma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013 , 139, 987-94	4.9	15
57	Effect of shell-crosslinking of micelles on endocytosis and exocytosis: acceleration of exocytosis by crosslinking. <i>Biomaterials Science</i> , 2013 , 1, 265-275	7.4	36
56	Minocycline inhibits malignant ascites of ovarian cancer through targeting multiple signaling pathways. <i>Gynecologic Oncology</i> , 2013 , 129, 113-9	4.9	20
55	Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer. <i>Cytokine and Growth Factor Reviews</i> , 2013 , 24, 163-73	17.9	65
54	Minocycline targets the NF- κ B Nexus through suppression of TGF- β -TAK1- $\text{I}\kappa$ B signaling in ovarian cancer. <i>Molecular Cancer Research</i> , 2013 , 11, 1279-91	6.6	39
53	MUC1 has prognostic significance in malignant peritoneal mesothelioma. <i>International Journal of Biological Markers</i> , 2013 , 28, 303-12	2.8	8
52	A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. <i>Oncotarget</i> , 2013 , 4, 502-30	3.3	131
51	Minocycline suppresses interleukine-6, its receptor system and signaling pathways and impairs migration, invasion and adhesion capacity of ovarian cancer cells: in vitro and in vivo studies. <i>PLoS ONE</i> , 2013 , 8, e60817	3.7	35
50	Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma. <i>American Journal of Cancer Research</i> , 2013 , 3, 411-23	4.4	7
49	Minocycline inhibits growth of epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2012 , 125, 433-40	4.9	29
48	Comparison of Shell-Cross-Linked Micelles with Soft and Glassy Cores as a Drug Delivery Vehicle for Albendazole: Is There a Difference in Performance?. <i>Macromolecules</i> , 2012 , 45, 5451-5462	5.5	31
47	Diffuse malignant peritoneal mesothelioma--an update on treatment. <i>Cancer Treatment Reviews</i> , 2012 , 38, 605-12	14.4	63
46	Optimizing radioimmunoconjugate delivery in the treatment of solid tumor. <i>Cancer Treatment Reviews</i> , 2012 , 38, 854-60	14.4	20
45	Effect of cross-linking on the performance of micelles as drug delivery carriers: a cell uptake study. <i>Biomacromolecules</i> , 2012 , 13, 814-25	6.9	66
44	Initial report on differential expression of sprouty proteins 1 and 2 in human epithelial ovarian cancer cell lines. <i>Journal of Oncology</i> , 2012 , 2012, 373826	4.5	10
43	Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application. <i>Journal of Oncology</i> , 2012 , 2012, 540791	4.5	10

42	HAX1 Augments Cell Proliferation, Migration, Adhesion, and Invasion Induced by Urokinase-Type Plasminogen Activator Receptor. <i>Journal of Oncology</i> , 2012 , 2012, 950749	4.5	14
41	Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. <i>Cancer and Metastasis Reviews</i> , 2012 , 31, 143-62	9.6	133
40	Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer. <i>Cancer Letters</i> , 2011 , 300, 122-33	9.9	18
39	Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. <i>PLoS ONE</i> , 2011 , 6, e24405	3.7	19
38	Peritoneal mesothelioma in a woman who has survived for seven years: a case report. <i>Journal of Medical Case Reports</i> , 2011 , 5, 36	1.2	2
37	An optimized RGD-decorated micellar drug delivery system for albendazole for the treatment of ovarian cancer: from RAFT polymer synthesis to cellular uptake. <i>Macromolecular Bioscience</i> , 2011 , 11, 219-33	5.5	33
36	Triggering the fast release of drugs from crosslinked micelles in an acidic environment. <i>Journal of Materials Chemistry</i> , 2011 , 21, 12777		38
35	Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis. <i>Biochemical and Biophysical Research Communications</i> , 2010 , 397, 729-34	3.4	46
34	Novel protein interactors of urokinase-type plasminogen activator receptor. <i>Biochemical and Biophysical Research Communications</i> , 2010 , 399, 738-43	3.4	16
33	Enhanced cytotoxicity of benzimidazole carbamate derivatives and solubilisation by encapsulation in cucurbit[n]uril. <i>Organic and Biomolecular Chemistry</i> , 2010 , 8, 3328-37	3.9	39
32	Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 65, 597-605	3.5	53
31	Potent inhibition of tumoral hypoxia-inducible factor 1 α by albendazole. <i>BMC Cancer</i> , 2010 , 10, 143	4.8	39
30	The influence of ovarian cancer induced peritoneal carcinomatosis on the pharmacokinetics of albendazole in nude mice. <i>Anticancer Research</i> , 2010 , 30, 423-8	2.3	4
29	Urokinase plasminogen activator system as a potential target for cancer therapy. <i>Future Oncology</i> , 2009 , 5, 1487-99	3.6	69
28	Inhibition of cell proliferation, vascular endothelial growth factor and tumor growth by albendazole. <i>Cancer Investigation</i> , 2009 , 27, 171-7	2.1	26
27	Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole. <i>Anticancer Research</i> , 2009 , 29, 3791-6	2.3	45
26	Solubilisation and cytotoxicity of albendazole encapsulated in cucurbit[n]uril. <i>Organic and Biomolecular Chemistry</i> , 2008 , 6, 4509-15	3.9	95
25	Inhibitors of vascular endothelial growth factor in cancer. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2008 , 6, 343-7	1.9	31

24	Albendazole-cyclodextrin complex: enhanced cytotoxicity in ovarian cancer cells. <i>Anticancer Research</i> , 2008 , 28, 2775-9	2.3	28
23	Inhibition of hepatocellular cancer by EB1089: in vitro and in vivo study. <i>Anticancer Research</i> , 2008 , 28, 3757-61	2.3	37
22	Synthesis of semi-biodegradable crosslinked microspheres for the delivery of 1,25 dihydroxyvitamin D3 for the treatment of hepatocellular carcinoma. <i>European Polymer Journal</i> , 2007 , 43, 1754-1767	5.2	14
21	Epothilone-paclitaxel resistant leukemic cells CEM/dEpoB300 are sensitive to albendazole: Involvement of apoptotic pathways. <i>Biochemical Pharmacology</i> , 2007 , 74, 407-14	6	39
20	Pharmacokinetics of albendazole in New Zealand white rabbits: oral versus intraperitoneal administration. <i>Anticancer Research</i> , 2007 , 27, 417-22	2.3	10
19	Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. <i>Clinical Cancer Research</i> , 2006 , 12, 1928-35	12.9	77
18	Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis. <i>Cancer Chemotherapy and Pharmacology</i> , 2005 , 55, 425-32	3.5	82
17	Regression of Novikoff rat hepatocellular carcinoma following locoregional administration of a novel formulation of clofazimine in lipiodol. <i>Cancer Letters</i> , 2004 , 207, 37-47	9.9	10
16	1,25-Dihydroxyvitamin D(3) induced cell cycle arrest in the human primary liver cancer cell line HepG2. <i>Hepatology Research</i> , 2003 , 26, 34-39	5.1	14
15	Estradiol alters afterdischarge threshold and acquisition of amygdala kindled seizures in male rats. <i>Neuroscience Letters</i> , 2003 , 340, 41-4	3.3	9
14	Hepatic arterial and intravenous administration of 1,25-dihydroxyvitamin D3—evidence of a clinically significant hepatic first-pass effect. <i>Cancer Chemotherapy and Pharmacology</i> , 2001 , 48, 209-14	3.5	9
13	Effects of chronic estradiol benzoate treatment on amygdala kindled seizures in male rats. <i>Epilepsy Research</i> , 2001 , 46, 45-51	3	9
12	The acute effects of estradiol benzoate on amygdala-kindled seizures in male rats. <i>Brain Research</i> , 2001 , 891, 1-6	3.7	23
11	Pilot study of albendazole in patients with advanced malignancy. Effect on serum tumor markers/high incidence of neutropenia. <i>Oncology</i> , 2001 , 61, 42-6	3.6	49
10	In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. <i>Cancer Letters</i> , 2001 , 165, 43-9	9.9	105
9	Intraperitoneal and intraamygdala N(6)-cyclohexyladenosine suppress hippocampal kindled seizures in rats. <i>Brain Research</i> , 2000 , 858, 48-54	3.7	14
8	In vitro and in vivo inhibition of liver cancer cells by 1,25-dihydroxyvitamin D3. <i>Cancer Letters</i> , 2000 , 151, 97-102	9.9	51
7	Anticonvulsant action of 2-chloroadenosine injected focally into the perirhinal cortex in amygdaloid kindled rats. <i>Epilepsy Research</i> , 1999 , 37, 37-43	3	14

6	Evaluation of the anticonvulsant activity of the essential oil of <i>Eugenia caryophyllata</i> in male mice. <i>Journal of Ethnopharmacology</i> , 1999 , 64, 167-71	5	55
5	The fruit essential oil of <i>Pimpinella anisum</i> exerts anticonvulsant effects in mice. <i>Journal of Ethnopharmacology</i> , 1999 , 66, 211-5	5	67
4	Evaluation of the anticonvulsant profile of progesterone in male amygdala-kindled rats. <i>Epilepsy Research</i> , 1998 , 30, 195-202	3	36
3	Effect of intraperitoneal and intrahippocampal (CA1) 2-chloroadenosine in amygdaloid kindled rats. <i>Brain Research</i> , 1997 , 751, 259-64	3.7	19
2	Intra-amygdala infusion of 2-chloroadenosine suppresses amygdala-kindled seizures. <i>Brain Research</i> , 1997 , 775, 37-42	3.7	20
1	Evidence for serotonergic system involvement in the effect of morphine on gastrointestinal motility in the rat. <i>General Pharmacology</i> , 1995 , 26, 779-83		6